News:
Treventis attends RESI Nov 2021
Treventis CEO Christopher Barden attended the second of the fall Redefining Early Stage Investments (RESI) conferences (held virtually this year...
Read More
Treventis attends RESI Nov 2021
Treventis CEO Christopher Barden attended the second of the fall Redefining Early Stage Investments (RESI) conferences (held virtually this year...
Read More
News:
Treventis attends RESI Nov 2021
Treventis CEO Christopher Barden attended the second of the fall Redefining Early Stage Investments (RESI) conferences (held virtually this year...
Read More
Treventis attends RESI Nov 2021
Treventis CEO Christopher Barden attended the second of the fall Redefining Early Stage Investments (RESI) conferences (held virtually this year...
Read More
TREVENTIS™ utilizes a proprietary, patented discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets.
CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets.
Our Takeda-partnered lead program focuses on anti-misfolding small molecules in Alzheimer’s disease. We have further CCM-driven, U.S. DOD-funded efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.
Treventis has active
druggable CCM models for
Tau
Alpha Synuclein
p53
Amylin
And the Potential to Make 160+ Others…
